NeuroPace (NPCE) Competitors $9.11 -0.24 (-2.57%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$9.10 -0.01 (-0.16%) As of 07/16/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. AORT, CDRE, ESTA, TNDM, FNA, BLFS, LQDA, SSII, PLSE, and INMDShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), Pulse Biosciences (PLSE), and InMode (INMD). These companies are all part of the "medical equipment" industry. NeuroPace vs. Its Competitors Artivion Cadre Establishment Labs Tandem Diabetes Care Paragon 28 BioLife Solutions Liquidia Technologies SS Innovations International Pulse Biosciences InMode Artivion (NYSE:AORT) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Which has more risk and volatility, AORT or NPCE? Artivion has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Is AORT or NPCE more profitable? Artivion has a net margin of -5.49% compared to NeuroPace's net margin of -29.42%. Artivion's return on equity of 3.63% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Artivion-5.49% 3.63% 1.34% NeuroPace -29.42%-190.84%-25.08% Does the media prefer AORT or NPCE? In the previous week, Artivion had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Artivion and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.89 beat Artivion's score of 0.10 indicating that NeuroPace is being referred to more favorably in the news media. Company Overall Sentiment Artivion Neutral NeuroPace Very Positive Do insiders and institutionals hold more shares of AORT or NPCE? 86.4% of Artivion shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 7.6% of Artivion shares are owned by insiders. Comparatively, 20.5% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate AORT or NPCE? Artivion presently has a consensus price target of $32.40, suggesting a potential upside of 2.94%. NeuroPace has a consensus price target of $17.00, suggesting a potential upside of 86.61%. Given NeuroPace's higher probable upside, analysts plainly believe NeuroPace is more favorable than Artivion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17NeuroPace 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, AORT or NPCE? Artivion has higher revenue and earnings than NeuroPace. Artivion is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtivion$390.08M3.45-$13.36M-$0.50-62.95NeuroPace$79.91M3.74-$27.14M-$0.84-10.85 SummaryArtivion beats NeuroPace on 10 of the 16 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$306.67M$6.58B$5.51B$9.31BDividend YieldN/A1.30%4.25%4.08%P/E Ratio-10.8525.4928.1519.68Price / Sales3.7467.67439.01100.25Price / CashN/A20.0535.5357.53Price / Book33.744.668.235.67Net Income-$27.14M$174.76M$3.23B$257.51M7 Day Performance-10.42%-1.59%-0.56%-0.16%1 Month Performance-15.49%3.25%6.67%9.89%1 Year Performance21.30%3.69%27.00%15.08% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.5724 of 5 stars$9.11-2.6%$17.00+86.6%+13.6%$306.67M$79.91M-10.85170AORTArtivion2.3644 of 5 stars$30.22-1.6%$32.40+7.2%+10.6%$1.31B$388.54M-60.441,600CDRECadre2.946 of 5 stars$31.84-1.2%$37.50+17.8%-16.4%$1.31B$567.56M33.522,284ESTAEstablishment Labs2.3987 of 5 stars$46.11+5.9%$52.40+13.6%-10.9%$1.26B$166.02M-14.871,018Positive NewsAnalyst ForecastTNDMTandem Diabetes Care4.1218 of 5 stars$16.25-3.2%$33.43+105.7%-66.5%$1.12B$940.20M-5.852,650Positive NewsAnalyst RevisionFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+59.8%$1.10B$256.18M-17.71343,000High Trading VolumeBLFSBioLife Solutions2.0157 of 5 stars$21.81-4.5%$31.17+42.9%-7.6%$1.08B$82.25M-75.20440Positive NewsLQDALiquidia Technologies3.2192 of 5 stars$12.45+2.1%$26.89+116.0%+10.6%$1.04B$14M-7.8850Trending NewsInsider TradeSSIISS Innovations InternationalN/A$5.27-1.3%N/AN/A$1.03B$20.65M0.004PLSEPulse Biosciences3.7362 of 5 stars$15.81+3.3%$22.00+39.2%-18.5%$1.03B$700K0.00140INMDInMode4.0933 of 5 stars$15.10-0.4%$18.54+22.8%-25.2%$958.25M$394.82M6.48480Positive News Related Companies and Tools Related Companies Artivion Alternatives Cadre Alternatives Establishment Labs Alternatives Tandem Diabetes Care Alternatives Paragon 28 Alternatives BioLife Solutions Alternatives Liquidia Technologies Alternatives SS Innovations International Alternatives Pulse Biosciences Alternatives InMode Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NPCE Stock Alerts